Taysha gene therapies announces poster presentation on tsha-102 in rett syndrome at upcoming british paediatric neurology association 2024 annual conference

Dallas, jan. 22, 2024 (globe newswire) -- taysha gene therapies, inc. (nasdaq: tsha), a clinical-stage gene therapy company focused on developing and commercializing aav-based gene therapies for the treatment of monogenic diseases of the central nervous system (cns), today announced that it will present clinical data on its tsha-102 program in evaluation for rett syndrome during an oral poster presentation at the upcoming british paediatric neurology association (bpna) 2024 annual conference, taking place in bristol, england from january 24-26, 2024.
TSHA Ratings Summary
TSHA Quant Ranking